<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847219</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190926-01</org_study_id>
    <nct_id>NCT04847219</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Premixed Insulin Treatment in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Efficacy and Safety of Premixed Insulin Treatment in Patients With Type 2 Diabetes Mellitus Observed by Different Type of Flash Glucose Mornitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuxi Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi People's Hospital Affiliated to Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huai'an Second People's Hospital and the Affiliated Huai'an Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Suqian First People's Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the efficacy and safety of premixed insulin treatment&#xD;
      in patients With type 2 diabetes mellitus using professional and personal Flash Glucose&#xD;
      Mornitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Professional and personal Flash Glucose Mornitoring will be used in patients with type 2&#xD;
      diabetes who are treated with premixed insulin. The frequency of hypogycemia and the blood&#xD;
      glucose control will be analyzed by flash glucose mornitoring once a month for 3 months and&#xD;
      doctors will adjust the hypoglycemia treatment according to the results every month. HbA1c,&#xD;
      glycemic variation, beta-cell function and androgen levels will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TIme in range</measure>
    <time_frame>baseline and after 3 month</time_frame>
    <description>change of TIme in range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>after 3 month</time_frame>
    <description>change of glycated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibody of insulin</measure>
    <time_frame>baseline and after 3 month</time_frame>
    <description>antibody of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>angrogen levels</measure>
    <time_frame>baseline and after 3 month</time_frame>
    <description>angrogen levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise time daily</measure>
    <time_frame>baseline and after 3 month</time_frame>
    <description>duration of exercise daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>meal times</measure>
    <time_frame>baseline and after 3 month</time_frame>
    <description>daily times of meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>calorie intake</measure>
    <time_frame>baseline and after 3 month</time_frame>
    <description>daily calorie intake</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Professional flash glucose mornitoring</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Professional flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via capillary blood glucose tests, but nor FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Personal flash glucose mornitoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Personal flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Professional flash glucose mornitoring</intervention_name>
    <description>Subjects will use Professional flash glucose mornitoring once a month for 3 months.</description>
    <arm_group_label>Professional flash glucose mornitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Personal flash glucose mornitoring</intervention_name>
    <description>Subjects will use Personal flash glucose mornitoring once a month for 3 months.</description>
    <arm_group_label>Personal flash glucose mornitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. participate voluntarily and sign the subject informed consent before the test.&#xD;
&#xD;
          2. for patients with type 2 diabetes who met WHO1999 diagnostic criteria, subcutaneous&#xD;
             injection with premix insulin Bid/Tid, single drug and/or combination of oral&#xD;
             hypoglycemic drugs, the treatment regimen was stable for more than 2 months.&#xD;
&#xD;
          3. no acute complications such as diabetic ketoacidosis and diabetic hyperosmolar&#xD;
             syndrome.&#xD;
&#xD;
          4. subjects are able and willing to undergo FGM examination, diet and exercise regularly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients treated with GLP-1 agonist in the last 3 months&#xD;
&#xD;
          2. patients who are allergic to insulin.&#xD;
&#xD;
          3. impaired liver and renal function, ALT 2.5 times higher than the upper limit of normal&#xD;
             value;Serum creatinine was 1.3 times higher than the upper limit of normal.&#xD;
&#xD;
          4. a history of drug abuse and alcohol dependence within the past 5 years.&#xD;
&#xD;
          5. used systemic hormone therapy in recent 3 months.&#xD;
&#xD;
          6. patients with poor compliance and irregular diet and exercise.&#xD;
&#xD;
          7. patients with infection and stress within four weeks.&#xD;
&#xD;
          8. patients who cannot tolerate flash glucose mornitoring.&#xD;
&#xD;
          9. patients who are pregnant, nursing or or preparing to become pregnant.&#xD;
&#xD;
         10. any other apparent condition or comorption as determined by the investigator, such as&#xD;
             severe heart and lung disease, endocrine disease, neurological disease, tumor disease,&#xD;
             other pancreatic disease, history of mental illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Ma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

